| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 12/07/2004 | US6827925 Specific binding proteins including antibodies which bind to the necrotic center of tumors, and uses thereof |
| 12/07/2004 | CA2158834C Antisense oligos which interfere with mrna cap activity and inhibit translation |
| 12/07/2004 | CA2154668C Condensed heterocyclic glutamic acid derivatives as antiproliferative agents |
| 12/07/2004 | CA2108817C Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation |
| 12/02/2004 | WO2004104575A2 Diagnostics and therapeutics for diseases associated with x-prolyl aminopeptidase 2 (xpnpep2) |
| 12/02/2004 | WO2004104200A1 Method of controlling cell proliferation by using novel function of myeloid leukemia factor mlf1 and utilization of the same |
| 12/02/2004 | WO2004104007A1 Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors |
| 12/02/2004 | WO2004104003A1 Novel pyridopyrazines and use thereof as kinase modulators |
| 12/02/2004 | WO2004104002A1 Novel pyridopyrazines and use thereof as kinase inhibitors |
| 12/02/2004 | WO2004103992A1 2-aminoquinoline derivative |
| 12/02/2004 | WO2004103987A1 Drug for nervous disorder |
| 12/02/2004 | WO2004103984A1 Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors |
| 12/02/2004 | WO2004103971A1 Cyclic aminophenyl sulfamate derivative |
| 12/02/2004 | WO2004103968A1 Sulfopyrroles |
| 12/02/2004 | WO2004103409A1 Antitumor agent and process for producing the same |
| 12/02/2004 | WO2004103406A1 Therapeutic composition for disease accompanied by decrease or increase of platelet |
| 12/02/2004 | WO2004103396A1 Compositions for enhanced mucosal delivery of interferon alpha |
| 12/02/2004 | WO2004103384A1 Pharmaceutical active agent containing a peptide toxin extracted from the venom of snakes in the genus crotalus |
| 12/02/2004 | WO2004103374A2 Imatinib combinations for head and neck cancers |
| 12/02/2004 | WO2004103369A1 Pharmaceutical composition containing histone deacetylase inhibitor |
| 12/02/2004 | WO2004103358A2 Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 12/02/2004 | WO2004078746A3 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
| 12/02/2004 | WO2004060264A3 Metastin derivatives and their use |
| 12/02/2004 | WO2004026815A3 Phenol derivatives and their use as rotamase inhibitors |
| 12/02/2004 | WO2003085377A3 Novel pancortin-pablo protein interactions and methods of use thereof |
| 12/02/2004 | WO2003078465A8 The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1 |
| 12/02/2004 | WO2003064665A3 Viral vector |
| 12/02/2004 | WO2003025119A3 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
| 12/02/2004 | WO2003011106A3 Internal image antibodies for optical imaging and therapy |
| 12/02/2004 | US20040243606 Hormonal contraceptive product |
| 12/02/2004 | US20040243316 Crystallographic structure of the androgen receptor ligand binding domain |
| 12/02/2004 | US20040242953 Endocurietherapy |
| 12/02/2004 | US20040242928 Reverse hydroxamic acid derivatives |
| 12/02/2004 | US20040242886 Induction apoptosis in tumor cells; antitumor, anticancer agents |
| 12/02/2004 | US20040242868 Controlling cytokines; antiinflammatory agents; rheumatic disoreders; skin disorders; respiratory system disorders; Alzheimer's disease; Parkinson's disease; Huntington"s disease ; amyotrophic lateral sclerosis |
| 12/02/2004 | US20040242860 Compositions and methods for the diagnosis and treatment of tumor |
| 12/02/2004 | US20040242852 Bifunctional chelating agent for actinium |
| 12/02/2004 | US20040242851 Immunoglobulin specifiic for vascular endothelial growth factor receptor for use in treatment and prevention of tumor; angiogenesis inhibitors; antitumor agents; antimetastasis agents; immunotherapy |
| 12/02/2004 | US20040242842 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use |
| 12/02/2004 | US20040242705 administering 1-(4-chloro-3-methylsulphonylphenyl)-1 -(4-chlorophenyl)-2,2-dichloroethene containing a radio labelled halogen |
| 12/02/2004 | US20040242675 Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor |
| 12/02/2004 | US20040242674 For example, (2'R,3'R)-13-[N-benzoyl-3-(2-furyl)-2-methyl-isoserinoyl]-baccatin III, (2'R,3'R)-13-[N-t-butoxycarbonyl-3-(2-furyl)-2-methyl-isoserinoyl]-baccatin III; antitumor activity against cancer cells of the breast, lung, ovary, colon, prostate, kidney, pancreas |
| 12/02/2004 | US20040242672 Pyrrolidine derivatives |
| 12/02/2004 | US20040242659 Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof |
| 12/02/2004 | US20040242656 N-heterocyclicamide compounds; useful in the treatment of cardiovascular disorders, in particular, as an anticoagulant |
| 12/02/2004 | US20040242647 Use of organic compounds |
| 12/02/2004 | US20040242637 drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals |
| 12/02/2004 | US20040242636 Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity |
| 12/02/2004 | US20040242628 administering N-(1H-Indol-7-yl)-4-nitrobenzenesulfonamide; treating cachexia during cancer therapy |
| 12/02/2004 | US20040242627 2-Iminoimidazole derivatives (1) |
| 12/02/2004 | US20040242606 Anti-cancer cyclopenta (g)quinazoline compounds |
| 12/02/2004 | US20040242604 Substituted heterocycles for the treatment of abnormal cell growth |
| 12/02/2004 | US20040242603 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same |
| 12/02/2004 | US20040242600 tyrosine kinase inhibitors; for the treatment especially of a proliferative disease, such as a tumur |
| 12/02/2004 | US20040242595 Pyrimidine derivatives |
| 12/02/2004 | US20040242578 Pyrimidineamines as angiogenesis modulators |
| 12/02/2004 | US20040242574 Anticancer agents; antiarthritic agents |
| 12/02/2004 | US20040242573 Novel compounds |
| 12/02/2004 | US20040242570 Conjugated psychotropic drugs and uses thereof |
| 12/02/2004 | US20040242564 1,2,3,4-tetrahydroisoquinolines derivatives |
| 12/02/2004 | US20040242534 Lyophilized powder of lentinan and the process of preparation thereof |
| 12/02/2004 | US20040242515 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy home-ostasis |
| 12/02/2004 | US20040242514 Xenogenic oligo or/and polyribonucleotides as agents for the treatment of malignant tumours |
| 12/02/2004 | US20040242508 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing the same |
| 12/02/2004 | US20040242507 Topical formulations of a lipophilic anthracycline with a second active ingredient and carrier; antiproliferative agents for skin and mucus membrane disorders; side effect reduction in psoriasis treatment with valrubicin |
| 12/02/2004 | US20040242481 Use of hmgb1 for the activation of dendritic cells |
| 12/02/2004 | US20040242479 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells |
| 12/02/2004 | US20040242416 Compositions and methods for intracellular delivery |
| 12/02/2004 | US20040241805 Cell surface binding protein for use in treatment, diagnosis and prevention of cancer, inflammation, autoimmunity, allergy, asthma and nervous system disorders |
| 12/02/2004 | US20040241803 25 human secreted proteins |
| 12/02/2004 | US20040241745 Substance specific to pd-1 |
| 12/02/2004 | US20040241705 Method of determining a chemotherapeutic regimen based on glutathione-s-transferase pi |
| 12/02/2004 | US20040241682 Cancer |
| 12/02/2004 | US20040241671 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their us as medicines |
| 12/02/2004 | US20040241249 Prepared by ketone extraction of krill; evaporating ketone in liquid product; 2nd extraction of the solids in the product with an alcohol or acetate solvent to form a soluble lipid fraction; separating liquids and solids in 2nd product and evaporating solvent from liquid fraction; recovering solids |
| 12/02/2004 | US20040241248 Crosslinking the carboxylic acid groups in a glycosaiminoglycan with a primary amine in a lipid to form particles that can be used to encapsulate various drugs, especially chemotherapeutic agents |
| 12/02/2004 | US20040241228 Spirolaxine acts as active principle in association with all-trans retinoic acid for treatment of those pathologies responding to activation of PPAR gamma receptor, such as acute malignant haemopathies. and Type 2 insulin-resistant diabetes |
| 12/02/2004 | US20040241204 Sustained release pharmaceutical composition |
| 12/02/2004 | US20040241176 Method of producing membrane vesicles |
| 12/02/2004 | US20040241160 Vegfr-1 antibodies to treat breast cancer |
| 12/02/2004 | US20040241158 Targetting antibodies containing haptens, cleaning agent, and drug delivery agent; tissue-directed therapy; solid phase synthesis |
| 12/02/2004 | US20040241156 Gene expression inhibition; solid phase synthesis; drug screening; for treating cancer, central nervous system disorders, and chronic obstructive pulmonary disorder |
| 12/02/2004 | US20040241147 antigen presenting cells which express major histocomatibility complexes, used as vaccines |
| 12/02/2004 | US20040241094 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| 12/02/2004 | US20040238781 Using genistein; preadministering before exposure to radiation; prevent tissue damage |
| 12/02/2004 | DE10322108A1 Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit Antiandrogens pyrrolidines with antitumor efficacy |
| 12/02/2004 | CA2634766A1 Pharmaceutical composition containing histone deacetylase inhibitor |
| 12/02/2004 | CA2634765A1 Pharmaceutical composition containing histone deacetylase inhibitor |
| 12/02/2004 | CA2634709A1 Pharmaceutical composition containing histone deacetylase inhibitor |
| 12/02/2004 | CA2527191A1 Cancer treatment comprising a histone deacetylase inhibitor and another anticancer agent |
| 12/02/2004 | CA2526908A1 Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 12/02/2004 | CA2526374A1 2-aminoquinoline derivatives |
| 12/02/2004 | CA2525840A1 Ovr115 antibody composition and methods of use |
| 12/02/2004 | CA2524948A1 Novel pyridopyrazines and use thereof as kinase inhibitors |
| 12/01/2004 | EP1482041A1 Nnl6 tie receptor tyrosine kinase ligand homologues |
| 12/01/2004 | EP1482040A2 NL3 TIE receptor tyrosine kinase ligand homologues |
| 12/01/2004 | EP1482037A1 Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation of small interfering RNA in vivo and in vitro |
| 12/01/2004 | EP1481993A1 Modulation of the poliovirus receptor function |
| 12/01/2004 | EP1481989A1 A-33 related antigens and their pharmacological uses |
| 12/01/2004 | EP1481983A1 Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof |